Cited by 1,392Pharmacology and Obesity TreatmentCannabis and Cannabinoid ResearchAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Open access

Després, Jean-Pierre, Golay, Alain, Sjöström, Lars·2005·New England Journal of Medicine

DOI 10.1056/nejmoa044537

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 months in addition to a hypocaloric diet. RESULTS: The rates of completion of the study were 62.6 percent, 60.3 percent, and 63.9 percent in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, respectively. The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea. As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P<0.001) mean weight loss (repeated-measures method, -6.7+/-0.5 kg, and last-observation-carried-forward analyses, -5.4+/-0.4 kg), reduction in waist circumference (repeated-measures method, -5.8+/-0.5 cm, and last-observation-carried-forward analyses, -4.7+/-0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0+/-1.6 percent, and last-observation-carried-forward analyses, +8.1+/-1.5 percent), and reduction in triglycerides (repeated-measures method, -13.0+/-3.5 percent, and last-observation-carried-forward analyses, -12.4+/-3.2 percent). Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone. CONCLUSIONS: Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.

Integrity signals

Registry

Crossref · 10.1056/nejmoa044537

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,782
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

10.2337/diabetes.46.10.1594 · DOI

Sorted by citations

Items 701–800 of 999

Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis
Mallat, A., & Lotersztajn, S. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74604-4 · Cited by 21
Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach
Foll, B. L., Pushparaj, A. P., Pryslawsky, Y., Forget, B., Vemuri, K. V., Makriyannis, A., & Trigo, J. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.009 · Cited by 20
Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes
Bura, S. A., Castañé, A., Ledent, C. A., Valverde, O., & Maldonado, R. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707152 · Cited by 21
Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease
Cortez‐Pinto, H., & Machado, M. V. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.2.217 · Cited by 21
Orosensory Detection of Dietary Fatty Acids Is Altered in CB1R−/− Mice
Brissard, L., Leemput, J., Hichami, A., Passilly‐Degrace, P., Maquart, G., Demizieux, L., Degrace, P., & Khan, N. A. (2018) · Nutrients · doi:10.3390/nu10101347 · Cited by 21
Peripheral Endocannabinoid System Activity in Patients Treated With Sibutramine
Engeli, S., Heusser, K., Janke, J., Gorzelniak, K., Bátkai, S., Pacher, P., Harvey-White, J. D., Luft, F. C., & Jordan, J. (2008) · Obesity · doi:10.1038/oby.2008.47 · Cited by 21
Low circulating maternal adiponectin in patients with pyelonephritis: adiponectin at the crossroads of pregnancy and infection
Mazaki‐Tovi, S., Romero, R. J., Vaisbuch, E., Chaiworapongsa, T., Erez, O., Mittal, P., Kim, S. K., Gotsch, F., Lamont, R., Oggè, G., et al. (2009) · Journal of Perinatal Medicine · doi:10.1515/jpm.2009.134 · Cited by 21
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen, A. J., Gaal, L. G. V., Després, J., Pi-Sunyer, X., Golay, A., & Hanotin, C. (2006) · PubMed · Cited by 21
Self-citation
Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome
Moscatiello, S., Luzio, R. D., Sasdelli, A. S., & Marchesini, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629188 · Cited by 20
Bedside to Bench: The element of surprise
Piomelli, D. (2008) · Nature Medicine · doi:10.1038/nm0708-720 · Cited by 20
How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue
Giraldo, J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.04.004 · Cited by 20
Are CB1 receptor antagonists nootropic or cognitive impairing agents?
Varvel, S. A., Wise, L. E., & Lichtman, A. H. (2009) · Drug Development Research · doi:10.1002/ddr.20334 · Cited by 20
Genome-wide Expression Profiling Revealed Peripheral Effects of Cannabinoid Receptor 1 Inverse Agonists in Improving Insulin Sensitivity and Metabolic Parameters
Zhao, W., Fong, O., Muise, E. S., Thompson, J. R., Weingarth, D. T., Qian, S., & Fong, T. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064980 · Cited by 20
Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
Dimmito, M. P., Stefanucci, A., Pieretti, S., Minosi, P., Dvorácskó, S., Tömböly, C., Zengin, G., & Mollica, A. (2019) · Biomolecules · doi:10.3390/biom9090492 · Cited by 20
Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats
Lamota, L., Bermúdez‐Silva, F. J., Marco, E. M., Llorente, R., Gallego, A., de Fonseca, F. R., & Viveros, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.004 · Cited by 20
Adipositas ist mehr als eine Essstörung - die multidimensionale Betrachtung einer Pandemie
Herpertz, S. (2008) · Zeitschrift für psychosomatische Medizin und Psychotherapie · doi:10.13109/zptm.2008.54.1.4 · Cited by 20
The endocannabinoid system and cardiometabolic risk
Szmitko, P. E., & Verma, S. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.011 · Cited by 21
Discovery and functional evaluation of diverse novel human CB1 receptor ligands
Foloppe, N., Benwell, K. R., Brooks, T., Kennett, G. A., Knight, A. R., Misra, A., & Monck, N. J. T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.114 · Cited by 20
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs
Marchesini, G., Moscatiello, S., Agostini, F., Villanova, N., & Festi, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.531700 · Cited by 20
Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy
Khedmat, H., & Taheri, S. (2011) · Hepatitis Monthly · Cited by 19
Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists
Iyer, M. R., Çınar, R., Liu, J., Godlewski, G., Szanda, G., Puhl, H. L., Ikeda, S. R., Deschamps, J. R., Lee, Y. S., Steinbach, P. J., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098541 · Cited by 19
Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors
Pertwee, R. G., & Thomas, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_13 · Cited by 20
6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB 1 ) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity
Yue-mei, Z., Greco, M. N., Macielag, M. J., Teleha, C. A., DesJarlais, R. L., Tang, Y., Ho, G., Hou, C., Chen, C., Zhao, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01467 · Cited by 19
Rimonabant reduces the essential value of food in the genetically obese Zucker rat: An exponential demand analysis
Rasmussen, E. B., Reilly, W., Buckley, J. L., & Boomhower, S. R. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.10.009 · Cited by 19
Targeted Inactivation of GPR26 Leads to Hyperphagia and Adiposity by Activating AMPK in the Hypothalamus
Chen, D., Liu, X., Zhang, W., & Shi, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040764 · Cited by 19
Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists
Gullapalli, S., Amrutkar, D. V., Gupta, S., Kandadi, M. R., Kumar, H., Gandhi, M. N., Karande, V. V., & Narayanan, S. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.03.001 · Cited by 19
Cannabis effects on lipoproteins
Lazarte, J., & Hegele, R. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000575 · Cited by 18
Association between plasma endocannabinoids and appetite in hemodialysis patients: A pilot study
Friedman, A. N., Kim, J. J., Kaiser, S., Pedersen, T. L., Newman, J. W. I., & Watkins, B. A. (2016) · Nutrition Research · doi:10.1016/j.nutres.2016.03.009 · Cited by 18
Role of microRNA in CB1 antagonist–mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity
Mehrpouya‐Bahrami, P., Miranda, K., Singh, N. P., Zumbrun, E. E., Nagarkatti, M., & Nagarkatti, P. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005094 · Cited by 18
Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target
Cavalheiro, E. K. F. F., Costa, A. B., Salla, D. H., da Silva, M. R., Mendes, T. F., da Silva, L. E., Turatti, C. D. R., de Bitencourt, R. M., & Rezin, G. T. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0016 · Cited by 22
Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
Jacquot, L., Pointeau, O., Roger-Villeboeuf, C., Passilly‐Degrace, P., Belkaid, R., Regazzoni, I., Leemput, J., Buch, C., Demizieux, L., Vergès, B. L., et al. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1138416 · Cited by 18
Effects of Chronic Oral Rimonabant Administration on Energy Budgets of Diet‐Induced Obese C57BL/6 Mice
Zhang, L., Gamo, Y., Sinclair, R. E., Mitchell, S. E., Morgan, D. G., Clapham, J. C., & Speakman, J. R. (2011) · Obesity · doi:10.1038/oby.2011.357 · Cited by 18
Cannabinoid receptor 1 and acute resistance exercise – In vivo and in vitro studies in human skeletal muscle
Pekkala, S., Wiklund, P., Hulmi, J. J., Pöllänen, E., Marjomäki, V., Munukka, E., Pierre, P., Mouly, V., Mero, A. A., Alén, M., et al. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.007 · Cited by 19
Safety of ephedra and related anorexic medications
Fleming, R. M. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802510915 · Cited by 18
Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010085 · Cited by 20
Lipidomics Reveals Multiple Pathway Effects of a Multi-Components Preparation on Lipid Biochemistry in ApoE*3Leiden.CETP Mice
Wei, H., Hu, C., Wang, M., van den Hoek, A. M., Reijmers, T. H., Wopereis, S., Bouwman, J., Ramaker, R., Korthout, H. A. A. J., Vennik, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030332 · Cited by 18
Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle.
Eid, B. G. (2018) · Europe PMC (PubMed Central) · doi:10.4103/jmau.jmau_42_18 · Cited by 18
Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation
Debenham, J. S., Madsen-Duggan, C. B., Wang, J., Tong, X., Lao, J. Z., Fong, T. M., Schaeffer, M., Xiao, J. C., Huang, C. R.-R. C., Shen, C.-P., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.005 · Cited by 18
Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese
Bennetzen, M., Nielsen, T. S., Paulsen, S. K., Bendix, J., Fisker, S., Jessen, N., Lund, S. A., Richelsen, B., & Pedersen, S. B. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02231.x · Cited by 21
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Knop, F. K., Kunos, G., Dicker, D., Paquette, J., Aronne, L. J., Frenkel, O., Holst‐Hansen, T., Lalonde, K., Lee, J., & Crater, G. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00216-5 · Cited by 17
Pharmacological efficacy and safety profile of taranabant in preclinical species
Fong, T. M., Shearman, L. P., Stribling, D. S., Shu, J., Lao, J., Huang, C. R. ‐., Xiao, J. C., Shen, C.-P., Tyszkiewicz, J. P., Strack, A. M., et al. (2009) · Drug Development Research · doi:10.1002/ddr.20311 · Cited by 17
Pharmacotherapy for obesity
Neff, L. M., & Aronne, L. J. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0061-0 · Cited by 17
O sistema endocanabinóide: novo paradigma no tratamento da síndrome metabólica
Godoy‐Matos, A. F., Guedes, E. P., de Souza, L. L., & Valério, C. M. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200025 · Cited by 17
Therapeutic Interventions to Enhance Apolipoprotein A-I-Mediated Cardioprotection
Haas, M. J., & Mooradian, A. D. (2010) · Drugs · doi:10.2165/11535410-000000000-00000 · Cited by 17
Three‐Component Synthesis of 3,4‐Disubstituted Pyrazoles Using Diazosulfone as a Diazomethane Surrogate
Ahamad, S., Patidar, R. K., Kumar, A., Kant, R., & Mohanan, K. (2017) · ChemistrySelect · doi:10.1002/slct.201702384 · Cited by 17
Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists
Pandey, P., Roy, K. K., Liu, H., Ma, G., Pettaway, S., Alsharif, W. F., Gadepalli, R. S., Rimoldi, J. M., McCurdy, C. R., Cutler, S. J., et al. (2018) · Molecules · doi:10.3390/molecules23102630 · Cited by 17
New agents in development for the management of obesity
Vincent, R. P., & le Roux, C. W. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01558.x · Cited by 17
Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J Mice
Tang, Y., Ho, G., Li, Y., Hall, M. A., Hills, R. L., Black, S. C., Liang, Y. T., & Demarest, K. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042134 · Cited by 18
Rimonabant, Gastrointestinal Motility and Obesity
Sun, Y., & Chen, J. D. Z. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217297 · Cited by 17
A common functional promoter variant links CNR1 gene expression to HDL cholesterol level
Feng, Q., Vickers, K. C., Anderson, M. P., Levin, M. G., Chen, W., Harrison, D. G., & Wilke, R. A. (2013) · Nature Communications · doi:10.1038/ncomms2973 · Cited by 16
Pharmacological Treatment of Obesity
Yoo, S. J. (2008) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2008.23.4.223 · Cited by 17
Pharmacogenetics: potential role in the treatment of diabetes and obesity
Vella, A., & Camilleri, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1109 · Cited by 17
Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease
Moradi, H., Park, C., Igarashi, M., Streja, E., Argueta, D. A., Soohoo, M., Daglian, J. M., You, A. S., Rhee, C. M., Kashyap, M. L., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00242 · Cited by 17
Variants at the Endocannabinoid Receptor CB1 Gene (CNR1) and Insulin Sensitivity, Type 2 Diabetes, and Coronary Heart Disease
de Miguel-Yanes, J. M., Manning, A. K., Shrader, P. J., McAteer, J. B., Goel, A., Hamsten, A., PROCARDIS, O. B. O., Fox, C. S., Florez, J. C., Dupuis, J., et al. (2011) · Obesity · doi:10.1038/oby.2011.135 · Cited by 17
Cannabinoids in Eating Disorders and Obesity
Árias, F. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0018-x · Cited by 17
High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention
Loves, S., van Groningen, L. F. J., Filius, M., Mekking, M., Brandon, T., Tack, C. J., Hermus, A. R., & de Boer, H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01147 · Cited by 16
Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB1 Receptor Antagonists after the Fall
Bosquez-Berger, T., Szanda, G., & Straiker, A. J. (2023) · Drugs and Drug Candidates · doi:10.3390/ddc2030035 · Cited by 17
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Pan, C., Yoo, H. J., & Ho, L.-T. (2010) · Journal of Obesity · doi:10.1155/2011/957268 · Cited by 16
Treatment of Hypertension in Obese Patients
Kidambi, S., & Kotchen, T. A. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0008-5 · Cited by 16
Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity
Vázquez‐Roque, M. I., Camilleri, M., Vella, A. V., Carlson, P., Laugen, J. M., & Zinsmeister, A. R. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01711.x · Cited by 16
The Metabolic Syndrome and Vascular Disease in Asia
Cheung, B. M. Y., & Thomas, G. N. (2007) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152907780830914 · Cited by 16
Does Rimonabant Independently Affect Free Fatty Acid and Glucose Metabolism?
Triay, J., Mundi, M. S., Klein, S., Toledo, F. G. S., Smith, S. R., Abu-Lebdeh, H. S., & Jensen, M. D. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2486 · Cited by 20
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates
Hjorth, S., Karlsson, C., Jučaitė, A., Varnäs, K., Hamrén, U. W., Johnström, P., Gulyás, B. Z., Donohue, S. R., Pike, V. W., Halldin, C., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.002 · Cited by 16
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
Mendes, D., Alves, C., & Marques, F. B. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1217989 · Cited by 16
Chapter 7 Cannabinoid Receptor CB1 Antagonists
Bifulco, M., Santoro, A., Laezza, C., & Malfitano, A. M. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(09)81007-8 · Cited by 16
Metabolic Syndrome Treatment Strategies
Fujioka, K. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12part2.222s · Cited by 16
Diabetes: Assessing the pipeline
Lebovitz, H. E. (2006) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2006.01.007 · Cited by 16
Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa
Torsello, A., Brambilla, F., Tamiazzo, L., Bulgarelli, I., Rapetti, D., Bresciani, E., & Locatelli, V. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03349245 · Cited by 16
The obesity pandemic
Kurukulasuriya, L. R., & Sowers, J. R. (2007) · Therapy · doi:10.2217/14750708.4.5.497 · Cited by 16
The Challenge of Treating Obesity: The Endocannabinoid System as a Potential Target
Isoldi, K. K., & Aronne, L. J. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.02.019 · Cited by 16
Cannabinoids hurt, heal in cirrhosis
Kunos, G., Osei‐Hyiaman, D., Bátkai, S., & Gao, B. (2006) · Nature Medicine · doi:10.1038/nm0606-608 · Cited by 16
Phosphorylation of hypothalamic AMPK on serine485/491 related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine
Kim, H., Park, M., Lee, S.-K., Jeong, J., Namkoong, K., Cho, H. S., Park, J. Y., Lee, B.-I., & Kim, E. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3540-3 · Cited by 15
The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes
Mikhailidis, D. P., & Press, M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.3009 · Cited by 15
Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice
van Eenige, R., Ying, Z., Tambyrajah, L. L., Pronk, A. C. M., Blomberg, N., Giera, M. A., Wang, Y., Coşkun, T., van der Stelt, M., Rensen, P. C. N., et al. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100070 · Cited by 15
Metabolic syndrome: the dysmetabolic state of dysfunctional adipose tissue and insulin resistance
Després, J., & Brewer, H. B. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sum051 · Cited by 15
Self-citation
Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients With Dyslipidemia
Bessesen, D. H. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70343-3 · Cited by 15
Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents
Rizvi, A. A., Nikolić, D., Sallam, H. S., Montalto, G., Rizzo, M., & Abate, N. I. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0090 · Cited by 15
Islet Cannabinoid Receptors
Flores, L. E., Alzugaray, M. E., Cubilla, M. A., Raschia, M. A., Zotto, H. H. D., Román, C. L., Suburo, Á. M., & Gagliardino, J. J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828fd32d · Cited by 15
Rimonabant for treating tobacco dependence.
Steinberg, M. B., & Foulds, J. (2007) · PubMed Central · Cited by 15
Management of obesity in the elderly: Too much and too late?
Kennedy, R. L., Malabu, U. H., Kazi, M., & Shahsidhar, V. (2008) · The journal of nutrition health & aging · doi:10.1007/bf03008271 · Cited by 15
From Active Ingredients to the Discovery of the Targets: The Cannabinoid Receptors
Mackie, K. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790148 · Cited by 15
Blood Pressure Lowering Effects of Rimonabant in Obesity‐related Hypertension
Grassi, G. M., Quarti‐Trevano, F., Seravalle, G., Arenare, F., Brambilla, G., & Mancia, G. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01688.x · Cited by 15
Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol
Toth, P. P. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693933 · Cited by 14
Association of Cardiometabolic Risk Factors and Prevalent Cardiovascular Events
Malone, D., Boudreau, D. M., Nichols, G. A., Raebel, M. A., Fishman, P. A., Feldstein, A. C., Ben-Joseph, R. H., Okamoto, L. J., Boscoe, A. N., & Magid, D. J. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0033 · Cited by 15
Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats
Ward, S. J., Lefever, T. W., Rawls, S. M., Whiteside, G. T., & Walker, E. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1592-6 · Cited by 15
Update on lipid-lowering therapy and LDL-cholesterol targets
Wiviott, S. D., & Cannon, C. P. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0613 · Cited by 15
Inhibitors of cannabinoid receptors and glucose metabolism
Scheen, A. J., & Paquot, N. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282fcea11 · Cited by 15
Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors
Jensen, M. D. (2006) · Obesity · doi:10.1038/oby.2006.294 · Cited by 15
Abnormal blood biomarkers and trajectories of depressive symptoms among Chinese middle-aged and older adults
Huang, J., Chen, L., Chen, H., Liu, Q., Tu, C., Dai, Y., Li, Y., & Tu, R. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112052 · Cited by 14
Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention
Margot, P. C. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/e30 · Cited by 14
Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol
Bishop, B. M. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828b8463 · Cited by 15
Pharmacologic Treatment Options for Obesity: Current and Potential Medications
Fujioka, K., & Lee, M. W. (2007) · Nutrition in Clinical Practice · doi:10.1177/011542650702200150 · Cited by 14
Obesity
Klein, S., & Romijn, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00036-8 · Cited by 14
Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?
Briand‐Mésange, F., Trudel, S., Salles, J., Ausseil, J., Salles, J., & Chap, H. (2020) · Obesity · doi:10.1002/oby.22916 · Cited by 14
Recent trials of lipid lowering
Ray, K. K., Cannon, C. P., & Braunwald, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01425.x · Cited by 16
Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women?
Milewicz, A., Tworowska-Bardzińska, U., Jędrzejuk, D., Lwow, F., Dunajska, K., Łaczmański, Ł., & Pawlak, M. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.145 · Cited by 14
Thermogenesis and Related Metabolic Targets in Anti-Diabetic Therapy
Arch, J. R. S. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_10 · Cited by 14
Fatty acid flux and oxidation are increased by rimonabant in obese women
Backhouse, K., Šarac, I., Shojaee‐Moradie, F., Stolinski, M., Robertson, M. D., Frost, G. S., Bell, J. D., Thomas, E. L., Wright, J., Russell-Jones, D. L., et al. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.012 · Cited by 14
Nonalcoholic fatty liver disease: from clinical recognition to treatment
Sevastianos, V., & Hadziyannis, S. J. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.1.59 · Cited by 14

Authors: Després, J.-P., Golay, A., & Sjöström, L.
Affiliations: Université Laval (CA)
University Hospital of Geneva (CH)
Sahlgrenska University Hospital (SE)
ORCID: Després, Jean-Pierre
Golay, Alain
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-11-17
Volume: 353
Issue: 20
Pages: 2121-2134
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa044537
OpenAlex: W2087587748
Cited by: 1,392
References: 38
Citations by year: 2026: 17 · 2025: 19 · 2024: 18 · 2023: 26 · 2022: 20 · 2021: 28 · 2020: 27 · 2019: 26 · 2018: 32 · 2017: 24 · 2016: 25 · 2015: 34 · 2014: 31 · 2013: 53 · 2012: 63
FWCI: 138.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: rimonabant, cannabinoid-1 receptor antagonist, dyslipidemia, overweight, obesity, weight loss, adiponectin, HDL cholesterol, triglycerides, waist circumference, hypocaloric diet, cardiovascular risk factors, dose comparison, body mass index, lipid-lowering therapy
MeSH terms: Rimonabant, Adult, Aged, Blood Glucose, Cholesterol, Double-Blind Method, Female, Humans, Insulin, Male, Middle Aged, Obesity, Piperidines, Pyrazoles, Risk Factors, Triglycerides, Weight Loss, Anti-Obesity Agents, Leptin, Metabolic Syndrome, Dyslipidemias, Overweight, Adiponectin, Cannabinoid Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks